AustraliaHealth

Dimerix (ASX:DXB) executed a licensing agreement with Everest Medicines to develop and commercialise its clinical-stage drug candidate, DMX-200.

Sigma Healthcare (ASX:SIG) has walked away from preliminary discussions to acquire UK health and beauty retailer Boots.

Echo IQ (ASX:EIQ) announced a research collaboration with Mayo Clinic to evaluate its proprietary artificial intelligence platform.

Neurizon Therapeutics (ASX:NUZ) announced that its HEALEY ALS Platform Trial has surpassed the critical 50% dosing milestone.

Monash IVF Group (ASX:MVF) revised its financial outlook for 2026, forecasting an underlying net profit after tax of between $17 million and $18 million.

Prescient Therapeutics (ASX:PTX) announced the appointment of Dr Rosalind Wilson as its new Chief Medical Officer, effective July 13.

Australian mental health prescriptions surge as nearly one in five citizens are prescribed psychiatric medications.

Island Pharmaceuticals (ASX:ILA) expands US Army partnership to advance a critical Galidesivir dose optimisation study.

Sigma Healthcare (ASX:SIG) is reportedly mulling a cross-border bid for British health and beauty giant Boots.

Integral Diagnostics (ASX:IDX) will initiate an independent audit following recent media reports alleging inappropriate billing practices in Western Australia.

Imugene (ASX:IMU) announced that the US FDA has granted Fast Track Designation to its novel therapy, azer-cel.

OncoSil Medical (ASX:OSL) enters the final stage of FDA review for its OncoSil device HDE application.